Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: A double-blind, placebo-controlled study of 329 patients

International Journal of Clinical Practice

Volumn 52, Issue 6, 1998, Pages 375-379

  Padma Nathan, H ^a,d   Steers, W D ^b   Wicker, P A ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HOT FLUSH; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; COITUS; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 0031659835     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83-90.
2. Foreman MM, Doherty PC. Experimental approaches to the development of pharmacological therapies for erectile dysfunction. In: Riley AJ, Peet M, Wilson CA, Eds. Sexual Pharmacology. Oxford: Oxford Medical Publications, 1993; 87-113.
3. Feldman HA, Goldstein I, Hatzichristou D et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
4. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995; 22: 699-709.
5. Kaiser FE, Viosca, SP, Morley JE et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988; 36: 511-519.
6. Rubin A, Babbott D. Impotence in diabetes mellitus. JAMA 1958; 168: 498-500.
7. Rundles RW. Diabetic neuropathy. Medicine 1945; 24: 111-160.
8. Kolodny RC, Kahn CB, Goldstein HH, Burnett DM. Sexual dysfunction in diabetic men. Diabetes 1973; 23: 306-309.
9. McCulloch DK, Campbell IW, Wu FC et al. The prevalence of diabetic impotence. Diabetologia 1980; 18: 279-283.
10. Abram HS, Hester LR, Sheridan WF, Epstein GM. Sexual functioning in patients with chronic renal failure. J Nerv Ment Dis 1975; 160: 220-226.
11. Cornely CM, Schade RR, Van Thiel DH, Gavalier JS. Chronic advanced liver disease and impotence: cause and effect? Hepatology 1984; 4: 1227-1230.
12. Goldstein I, Siroky MB, Sax DS, Krane RJ. Neurological abnormalities in multiple sclerosis. J Urol 1982; 128: 541-545.
13. Zeiss AM, Davies HD, Wood M, Tinklenberg JR. The incidence and correlates of erectile problems in patients with Alzheimer's disease. Arch Sex Behav 1990; 19: 325-331.
14. Fletcher EC, Martin RJ. Sexual dysfunction and erectile impotence in chronic obstructive pulmonary disease. Chest 1982; 81: 413-421.
15. Rajfer J, Aronson WJ, Bush PA et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-94.
16. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-261.
17. Rosen RC, Riley A, Wagner G et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
18. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-1404.
19. Guay AT. Erectile dysfunction: are you prepared to discuss it? Postgrad Med 1995; 97: 127-143.
20. Hanash KA. Comparative results of goal oriented therapy for erectile dysfunction. J Urol 1997; 157: 2135-2138.
21. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A. Outcome analysis of goal directed therapy for impotence. J Urol 1996; 155: 1609-1612.
22. Montague DK, Barada JR Belker AM et al. Clinical Guidelines Panel on Erectile Dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 1996; 156: 2007-2011.
23. Morales A, Condra M, Owen JA et al. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol 1987; 137: 1168-1172.
24. Susset JG, Tessier CD, Wincze J et al. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol 1989; 141: 1360-1363.
25. Teloken C, Rhoden EL, Sogan P et al. Therapeutic effects of high-dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998; 159: 122-124.
26. Kunelius P, Hakkinen J, Lukkarinen O. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urology 1997; 49: 441-444.
27. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159: 433-436.
28. Aydin S, Odabas O, Ercan M et al. Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. Br J Urol 1996; 77: 256-260.
29. Meinhardt W, Schmitz PI, Kropman RF et al. Trazodone, a double blind trial for treatment of erectile dysfunction. Int J Impot Res 1997; 9: 163-165.
30. Kurt U, Ozkardes H, Altug U et al. The efficacy of anti-serotonergic agents in the treatment of erectile dysfunction. J Urol 1994; 152: 407-709.
31. Gupta R, Kirschen J, Barrow RC, Eid JF. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 1997; 157: 1681-1686.
32. Sexton WJ, Benedict JF, Jarow JP. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urol 1998; 159: 811-815.
33. VIAGRA™ (package insert). New York: Pfizer Inc, 1998.